[go: up one dir, main page]

MX2023001947A - Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. - Google Patents

Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.

Info

Publication number
MX2023001947A
MX2023001947A MX2023001947A MX2023001947A MX2023001947A MX 2023001947 A MX2023001947 A MX 2023001947A MX 2023001947 A MX2023001947 A MX 2023001947A MX 2023001947 A MX2023001947 A MX 2023001947A MX 2023001947 A MX2023001947 A MX 2023001947A
Authority
MX
Mexico
Prior art keywords
protein conjugates
polysaccharide
streptococcus pneumoniae
protein
pneumoniae polysaccharide
Prior art date
Application number
MX2023001947A
Other languages
English (en)
Inventor
Jian He
Chitrananda Abeygunawardana
Luwy Musey
Hari Pujar
Julie M Skinner
Emily Wen
Patrick Mchugh
John Michael Williams
Catherine Lancaster
John E Macnair
William J Smith
Michael A Winters
Joseph G Joyce
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2023001947A publication Critical patent/MX2023001947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona composiciones inmunogénicas que tienen uno o más conjugados de polisacárido-proteína en los cuales uno o más polisacáridos de cápsulas bacterianas de Streptococcus pneumoniae se conjugan con una proteína vehículo en un solvente aprótico tal como dimetilsulfóxido (DMSO). La presente invención también proporciona métodos para proporcionar una respuesta inmunitaria mejorada a una vacuna de conjugado de polisacárido-proteína neumococo que comprende administrar a un sujeto humano una composición inmunogénica que comprende conjugados de polisacárido-proteína preparados en condiciones de DMSO.
MX2023001947A 2017-02-24 2019-08-19 Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. MX2023001947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762463216P 2017-02-24 2017-02-24
US201762555444P 2017-09-07 2017-09-07

Publications (1)

Publication Number Publication Date
MX2023001947A true MX2023001947A (es) 2023-03-14

Family

ID=63254065

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019009867A MX2019009867A (es) 2017-02-24 2018-02-20 Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
MX2023001948A MX2023001948A (es) 2017-02-24 2019-08-19 Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
MX2023001947A MX2023001947A (es) 2017-02-24 2019-08-19 Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2019009867A MX2019009867A (es) 2017-02-24 2018-02-20 Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
MX2023001948A MX2023001948A (es) 2017-02-24 2019-08-19 Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.

Country Status (10)

Country Link
US (4) US11090374B2 (es)
EP (1) EP3589314A4 (es)
JP (3) JP7680185B2 (es)
KR (2) KR20240011879A (es)
CN (1) CN110337307A (es)
AU (1) AU2018225099B2 (es)
BR (1) BR112019017560A2 (es)
CA (1) CA3050120A1 (es)
MX (3) MX2019009867A (es)
WO (1) WO2018156491A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102611449B1 (ko) * 2005-04-08 2023-12-06 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3957321A3 (en) * 2014-01-21 2022-07-13 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
JP6994453B2 (ja) * 2015-07-21 2022-01-14 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
BR112020004410A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
BR112020004396A8 (pt) * 2017-09-07 2023-01-31 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AR114154A1 (es) 2017-12-06 2020-07-29 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
JP7489324B2 (ja) 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
JP2022513562A (ja) * 2018-09-23 2022-02-09 バイオロジカル イー リミテッド 肺炎連鎖球菌の精製された莢膜多糖
KR20240169145A (ko) * 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
WO2020208502A1 (en) * 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220233674A1 (en) * 2019-06-05 2022-07-28 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
EP4101192A4 (en) * 2020-02-03 2024-02-28 Anagog Ltd. DELIVERY OF DISTRIBUTED CONTENT
IL297593A (en) * 2020-04-28 2022-12-01 Janssen Pharmaceuticals Inc Method for identification and quantification of polysaccharides in complex glycoconjugate compositions
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法
WO2024059161A1 (en) * 2022-09-16 2024-03-21 Merck Sharp & Dohme Llc Method for quantification of polysaccharide content in conjugate vaccines
CN120265317A (zh) 2022-11-22 2025-07-04 辉瑞公司 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
KR102611449B1 (ko) 2005-04-08 2023-12-06 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE050049T2 (hu) 2005-04-08 2020-11-30 Wyeth Llc Szennyezõanyagok elválasztása streptococcus pneumoniae poliszacharidtól PH manipulációjával
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CA2665169C (en) 2006-10-10 2017-02-21 Wyeth Purification of streptococcus pneumoniae type 3 polysaccharides
PL3406635T3 (pl) 2007-03-23 2022-08-22 Wyeth Llc Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
PT2379734T (pt) 2008-12-18 2018-04-27 Wyeth Llc Método para o controlo da massa molecular do polissacárido do serotipo 19a de streptococcus pneumoniae
WO2010080484A1 (en) 2008-12-18 2010-07-15 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
RU2531234C2 (ru) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
AR084158A1 (es) 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP4169929A1 (en) 2012-12-20 2023-04-26 Pfizer Inc. Immunogenic compositions comprising pn-serotype 12f
NZ760783A (en) * 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049825B1 (ko) * 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
EP3957321A3 (en) * 2014-01-21 2022-07-13 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
ES2793023T3 (es) * 2014-08-08 2020-11-12 Glaxosmithkline Biologicals Sa Células huésped modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados
HRP20230416T1 (hr) * 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
EP3292146A1 (en) 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
JP6994453B2 (ja) * 2015-07-21 2022-01-14 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
RU2761633C2 (ru) 2015-11-17 2021-12-13 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
PL3570879T3 (pl) 2017-01-20 2022-06-20 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
JP7254707B2 (ja) 2017-02-24 2023-04-10 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌コンジュゲートワクチン製剤
EP3585427A4 (en) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
KR20200040812A (ko) 2017-08-16 2020-04-20 머크 샤프 앤드 돔 코포레이션 폐렴구균 접합체 백신 제제
BR112020004410A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
BR112020004396A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
EP3700565A4 (en) 2017-10-25 2021-09-29 Merck Sharp & Dohme Corp. VACCINES WITH ADJUVANT
AR114154A1 (es) * 2017-12-06 2020-07-29 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
JP7489324B2 (ja) 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
US20210223262A1 (en) 2018-06-07 2021-07-22 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220233674A1 (en) 2019-06-05 2022-07-28 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
MX2021014948A (es) 2019-06-05 2022-01-24 Merck Sharp & Dohme Llc Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.

Also Published As

Publication number Publication date
US12295998B2 (en) 2025-05-13
US11090374B2 (en) 2021-08-17
JP2024112952A (ja) 2024-08-21
KR20190121330A (ko) 2019-10-25
AU2018225099A1 (en) 2019-07-25
CN110337307A (zh) 2019-10-15
RU2019129503A3 (es) 2021-06-25
US20240139303A1 (en) 2024-05-02
EP3589314A4 (en) 2021-04-21
US20210330778A1 (en) 2021-10-28
WO2018156491A1 (en) 2018-08-30
US20210330777A1 (en) 2021-10-28
BR112019017560A2 (pt) 2020-04-07
JP7680185B2 (ja) 2025-05-20
MX2023001948A (es) 2023-03-14
RU2019129503A (ru) 2021-03-24
EP3589314A1 (en) 2020-01-08
KR20240011879A (ko) 2024-01-26
AU2018225099B2 (en) 2024-08-22
JP2023036953A (ja) 2023-03-14
US20200054733A1 (en) 2020-02-20
MX2019009867A (es) 2019-10-02
JP2020514326A (ja) 2020-05-21
CA3050120A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2023001948A (es) Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
MX2020002556A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2020002555A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2022014850A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2024006606A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
MX394768B (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
NZ755769A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4286000A3 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PH12021551448A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MY204888A (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
ZA202103560B (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
IN2014DN09791A (es)
MX2020002084A (es) Conjugados de peptido, proceso de conjugacion y usos de los mismos.
EA201990451A1 (ru) Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение
BR112017028395A2 (pt) ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica?